<DOC>
	<DOCNO>NCT00057707</DOCNO>
	<brief_summary>This study evaluate whether modafinil improves cognition patient schizophrenia healthy volunteer . Modafinil drug FDA approve day-time sleepiness allegedly increase amount neurotransmitter dopamine frontal cortex brain</brief_summary>
	<brief_title>Effects Modafinil Brain Function Patients With Schizophrenia</brief_title>
	<detailed_description>Psychopharmacological modulation catecholaminergic system enhance aspect cognitive function . For example , COMT inhibitor slightly improve work memory/executive function . Similarly , modafinil , catecholaminergic agonist increase extracellular dopamine prefrontal cortex also show improve delay-dependent work memory . Differences response individual might relate number factor , include variation gene . The recent finding polymorphism catechol-o-methyl-transferase ( COMT ) gene , produce 4 fold change enzyme activity , account 4 % variance performance work memory task human suggest COMT genotype may predict response COMT inhibitor agonists increase catecholaminergic function frontal cortex . In present investigation goal examine , normal control patient schizophrenia , effect modafinil , drug increase DA output frontal cortex , cognitive function brain physiology . We predict normal control patient schizophrenia val/val genotype significant improvement work memory compare individual possess genotype . Furthermore , conjunction NIMH imaging protocol , predict modafinil produce similar genotype-dependent effect neurophysiological correlate related work memory assay fMRI . The present protocol provide new insight importance genetic polymorphism regulation aminergic-controlled cognitive function normal individual . Furthermore , protocol test whether modafinil offer new treatment -based genotype - cognitive impairment schizophrenia . The FDA grant waiver use Modafinil study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>INCLUSION CRITERIA : Prior participation NIH protocol # 95M0150 , new normal volunteer . Patients Schizophrenia Schizoaffective disorder meet criterion NIH protocol # 95M0150 include . No active Axis I Axis II diagnosis normal volunteer . Age range : 1850 year . EXCLUSION CRITERIA : Subjects history cardiovascular disease , liver disease medical illness , current active substance abuse history substance abuse 5 year , untreated uncontrolled hypertension exclude . Individuals persistent tardive dyskinesia exclude study . An electrocardiogram , blood pressure , pulse rate metabolic panel include LFTs check subject prior participation study . Schizophrenic patient take , COMT inhibitor , buproprion , stimulant , cognitive enhancer illicit drug abuse , MAO inhibitor exclude . Normal control subject take medication affect brain function exclude . Pregnant breastfeed woman . Women childbearing potential undergo urine pregnancy test day study initiate screen history possibility pregnancy . Patients significant history violence self others establish protocol # 89M0160 ( Inpatient Evaluation Neuropsychiatric Patients )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 20, 2016</verification_date>
	<keyword>Catecholamines</keyword>
	<keyword>Dopamine</keyword>
	<keyword>fMRI</keyword>
	<keyword>Working Memory</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Stabilization</keyword>
	<keyword>Inpatients</keyword>
	<keyword>Placebo</keyword>
	<keyword>Modafinil</keyword>
	<keyword>Normal Volunteers</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>